Clinical experience with the etanercept biosimilar SB4 in psoriatic patients.

07:00 EST 4th January 2019 | BioPortfolio

Summary of "Clinical experience with the etanercept biosimilar SB4 in psoriatic patients."

Background After the expiry of the patent of reference etanercept, several biosimilars have been developed, including SB4. Objective To study safety and efficacy of SB4 in psoriatic patients previously treated with etanercept and in the etanercept naive ones. Method Patients affected by moderate to severe psoriasis and/or psoriatic arthritis attending the Psoriasis Center of Florence University, treated with SB4 were enrolled in the study. Patients were divided in two cohorts. Cohort 1 included 32 patients who were switched from previous etanercept, cohort 2 included 12 patients who were naive to etanercept. Results Evaluation of the efficacy of SB4 in cohort 1 patients revealed rates of clinical remission (defined as both PASI and/or DAS28 increase < 10%) of 92% and 64% for psoriasis and psoriatic arthritis respectively. In cohort 2 at week 24 PASI 75 was observed in 75% of patients. Conclusion In our experience switching from originator to SB4 in psoriatic patients seems not to influence efficacy, especially cutaneous manifestations, over a median observational period of 24 weeks.


Journal Details

This article was published in the following journal.

Name: International journal of clinical pharmacy
ISSN: 2210-7711


DeepDyve research library

PubMed Articles [41321 Associated PubMed Articles listed on BioPortfolio]

Repeated switches between reference product etanercept and biosimilar do not affect disease activity or retention rate of etanercept over 24 months - a cohort study with historical controls.

Treatment of psoriatic arthritis with secukinumab: a case series.

Psoriatic arthritis (PsA) is a chronic inflammatory disorder affecting up to 30% of psoriatic patients, worsening patients' quality of life. Secukinumab, a fully humanized monoclonal antibody that sel...

Modulation of inflammatory gene transcripts in psoriasis vulgaris: differences between ustekinumab and etanercept.

Findings demonstrate differences in modulation of specific psoriatic inflammatory pathways between ustekinumab vs. etanercept responders. These data also.

Long-term etanercept survival in patients with psoriatic arthritis: a multicenter retrospective analysis in daily clinical practice in Spain.

Although several randomized clinical trials and observational studies have evaluated the effectiveness, safety and drug survival of etanercept (ETN) in the treatment of psoriatic arthritis (PsA), long...

Depression Symptoms Predict Worse Clinical Response to Etanercept Treatment in Psoriasis Patients.

This study aimed to investigate the predicting values of depression and anxiety symptoms for clinical response to etanercept treatment in psoriasis patients.

Clinical Trials [5353 Associated Clinical Trials listed on BioPortfolio]

Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis

The purpose of this study is to learn more about the role of etanercept alone or in combination with methotrexate on disease activity in subjects with psoriatic arthritis. To do this, eta...

Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis

To assess the efficacy of two different treatment regimens of etanercept in psoriasis subjects with psoriatic arthritis with respect to both the skin and joint manifestations.

Enbrel® in Psoriatic Arthritis

This study is testing the effect of etanercept in treating both the skin and joint symptoms of psoriatic arthritis patients. Enbrel®, also known as etanercept, has already been approved b...

Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists

The purpose of this study is to evaluate the safety profile and the effectiveness of Etanercept under usual care settings in patients with PsA treated by dermatologists.

Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists

The purpose of this study is to evaluate the safety and effectiveness of Etanercept under usual care settings in patients with PsA treated by rheumatologists.

Medical and Biotech [MESH] Definitions

A recombinant version of soluble human TNF receptor that binds specifically to TUMOR NECROSIS FACTOR and inhibits its binding with endogenous TNF receptors. It prevents the inflammatory effect of TNF and is used to treat RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS and ANKYLOSING SPONDYLITIS.

Undergraduate medical education programs for second- , third- , and fourth-year students in which the students receive clinical training and experience in teaching hospitals or affiliated health centers.

The separation or resolution of the psyche into its constituent elements. The term has two separate meanings: 1. a procedure devised by Sigmund Freud, for investigating mental processes by means of free association, dream interpretation and interpretation of resistance and transference manifestations; and 2. a theory of psychology developed by Freud from his clinical experience with hysterical patients. (From Campbell, Psychiatric Dictionary, 1996).

BIOLOGIC PRODUCTS that are imitations but not exact replicas of innovator products.

Heterogeneous group of arthritic diseases sharing clinical and radiologic features. They are associated with the HLA-B27 ANTIGEN and some with a triggering infection. Most involve the axial joints in the SPINE, particularly the SACROILIAC JOINT, but can also involve asymmetric peripheral joints. Subsets include ANKYLOSING SPONDYLITIS; REACTIVE ARTHRITIS; PSORIATIC ARTHRITIS; and others.

Quick Search


DeepDyve research library

Relevant Topic

Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Searches Linking to this Article